The role of EUS in diagnosis and treatment of liver disorders

Authors
Sara Campos1,2, Jan-Werner Poley2, Lydiva Driel2, Marco J. Bruno2

Institutions
1 Department of Gastroenterology, Hospital Garcia da Orta, Portugal
2 Department of Gastroenterology and Hepatology, Erasmus MC, The Netherlands

submitted 4.10.2018
accepted after revision 7.1.2019

Bibliography

Corresponding author
Sara Campos, Department of Gastroenterology, Hospital Garcia da Orta – Gastroenterology, Av. Torrado da Silva Almada, 2805-267, Portugal
Fax: +351 21 295 7004
sara.campos@hgo.min-saude.pt

ABSTRACT
Background and aim Transabdominal ultrasound (US), computed tomographic scanning (CT) and magnetic resonance imaging (MRI) are established diagnostic tools for liver diseases. Percutaneous transhepatic cholangiography is used to perform hepatic interventional procedures including biopsy, biliary drainage procedures, and radiofrequency ablation. Despite their widespread use, these techniques have limitations. Endoscopic ultrasound (EUS), a tool that has proven useful for evaluating the mediastinum, esophagus, stomach, pancreas, and biliary tract, has an expanding role in the field of hepatology complementing the traditional investigational modalities. This review aimed to assess the current scientific evidence regarding diagnostic and therapeutic applications of EUS for hepatic diseases.

Introduction
Transabdominal ultrasound (US), computed tomographic (CT) scanning and magnetic resonance imaging (MRI) are established diagnostic tools for liver diseases. In addition, percutaneous interventions, most commonly with US or CT-guidance, are often used to perform a wide range of liver and biliary interventional procedures, including: vascular interventions (as transjugular intrahepatic portosystemic shunt and transjugular liver biopsy), percutaneous interventions (such as liver biopsy, collections/abscess drainage and transhepatic biliary interventions, namely percutaneous transhepatic cholangiography and/or biliary drainage) and interventional oncologic therapeutic procedures (such as transarterial tumor embolization [hepatic radioembolization] and tumor ablations using thermal ablation techniques [radiofrequency ablation]). Despite their widespread use, these techniques have limitations. Endoscopic ultrasound (EUS), a first-line investigation method for evaluation of the mediastinum, esophagus, stomach, pancreas, and biliary tract, has an expanding role in the field of hepatology complementing the traditional investigational modalities. We aimed to review the current scientific evidence regarding diagnostic and therapeutic applications of EUS for hepatic diseases.

Search strategies and criteria
A search was performed in Pubmed with the keywords (liver OR hepatic) and (EUS OR "endoscopic ultrasound") and (diagnosis OR diagnostic OR treatment OR therapeutic OR ablation OR intervention). Inclusion criteria were: case reports, series, clinical studies, studies in animal models and reviews regarding EUS applications in liver disorders, including portal hypertension. Reports about the use of EUS in extrahepatic bile duct, gallbladder, and other extrahepatic structures were excluded. Non-English language literature without an English translation was also excluded. On March 4, 2018, the search yielded 1095 articles, 201 of which were included in this review.
Diagnostic role of EUS in liver disease

Technical considerations

To evaluate the liver with EUS, one must first take into account that its perspective of liver anatomy is much different from US or CT images and requires three-dimensional conceptualization of the liver parenchyma. The Couinaud classification [1] is the most widely used system to describe liver anatomy and divides the liver into eight (I-VIII) functionally independent units, termed segments, based on planes through the hepatic veins (HV) and the bifurcation of the main portal vein (PV) (Fig. 1).

With EUS, these liver segments are recognized by identifying the following structures: (1) PV branches with thick and hyper-echoic walls, Doppler positive; (2) HV branches (left and middle) with thin and non-reflective walls, straight course, Doppler positive; (3) biliary radicals with hyper-echoic walls, irregular course, Doppler negative; (4) ligaments (venosum and teres) with thick and hyper-echoic structures without lumen, extending between vessels and liver capsule; and (5) surface landmarks (gallbladder, falciform ligament and liver hilum). The longitudinal and cross-sectional schematic representations of linear EUS (Fig. 2) through the liver from the proximal stomach with a clockwise probe rotation from A-D (Fig. 2a) and from 1–4 (Fig. 2b) must be taken into account.

A step-by-step endosonographic evaluation of the liver is performed as described by Bhatia et al. [2]. From the stomach, it is possible to evaluate the left lateral segments (segments II and III), as well as the umbilical part of the left PV and ligamentum teres (l.t.), the medial segment of the left lobe (segment IV), ligamentum venosum (l.v.), the caudate lobe (segment I), the inferior vena cava (IVC), the right lobe (segments V and VIII) and the liver hilum. From the duodenal bulb, segments VI and VII, the hepatoduodenal ligament structures and PV and hepatic artery (HA) branches, the liver hilum and the segmental divisions of right PV and HA are visualized.

EUS has several potential advantages over other imaging modalities regarding optimal visualization of the liver: the EUS transducer can be positioned closely to the liver thereby avoiding interposing structures (such as rib cage, bowel loops, gall-bladder, pleural space, ascites and a thickened abdominal wall, which are all well-known limitations of, for example, transabdominal ultrasound [3]), and it has the potential to thoroughly evaluate the left liver lobe, hilum and deeply-located areas of the liver, such as the caudate lobe. One potential limitation is the evaluation of the right lobe. It is examined from the duodenum, which is technically difficult because of the small endosonographic window and is possibly further compounded by the limited depth of penetration of the ultrasound waves [4].

Doppler ultrasound, through different implementations (as continuous-wave, pulsed-wave, color and power Doppler), can be used to identify blood flow in vessels. It is useful for characterizing liver anatomy, identifying interposed vessels during punctures and evaluating portal hypertension (PHT). Regarding vascular changes in PHT, EUS-Doppler has a distinct advantage over endoscopy, as it can reveal not only gastroesophageal varices, but also collaterals adjacent to or outside the wall such as periesophageal collateral veins (peri-ECV), paraesophageal col-
lateral veins (para-ECV) collaterals and perforating veins [5–9]. Moreover, EUS can more accurately determine their size and wall thickness [10] and assess hemodynamic changes in portal and azygos veins and left gastric vessels, important parameters to consider for bleeding management.

Real-time elastography is another helpful tool that provides color-coded images and semi-quantitative measurements related to tissue stiffness of liver parenchyma and focal lesions as an additional tool in determining the etiology of the lesion. The need for manual tissue pressure required during standard transabdominal US elastography is overcome by comparing the ultrasound signals obtained over several seconds of normal breathing and blood circulation [11]. Also important is that elastography imaging via EUS is not limited by ascites and thickened abdominal wall [3].

Contrast-Enhancement (CE) is an emerging technique that is becoming more and more available to improve US and EUS diagnostical performance of focal liver lesions. CE-EUS is categorized into two types: CE-EUS with the Doppler method (CE-EUS-D) and CE-EUS with harmonic imaging (CE-EUS-H). CE-EUS-D helps distinguishing between vascular-rich and hypovascular areas of a target lesion. CE-EUS-H provides a more detailed vascular image of the target lesion. Both modes can be obtained to characterize a target lesion, and can be used depending on the purpose. Few US contrast agents are available worldwide, Sonovue and Sonazoid being the most widely used. These are made of microbubbles with a shell of phospholipids that are filled with sulfur hexafluoride gas. Since they are confined to the vessels after injection, it allows visualization of the tiny vessels in the capillary bed and therefore dynamic detection of capillary microvasculization. Given the dual blood supply of the liver, from the portal vein and the hepatic artery, three vascular phases can be observed with this ultrasound contrast: the arterial phase, beginning within 20 seconds after the injection and continuing for 30 to 45 seconds; the portal venous phase, that lasts up to 120 seconds; and then the late phase which persists until clearance of the US contrast agent from the circulation (usually 6 minutes). CE-EUS has several advantages over CT and MRI [12]: (1) It is performed in real time; (2) The contrast is not excreted by the kidneys, thus it does not need pre-investigational renal function testing and it can be used in patients with renal insufficiency, where contrast-enhanced CT or contrast-enhanced MRI are contraindicated; (3) Confinement in the vascular space without extravasation into the interstitial fluid allows a prolonged enhancement of the vascular system and the evaluation in the different vascular phases previously described; (4) It has a much higher resolution compared to other imaging modalities, enabling full study of the enhancement dynamics of lesions; and (5) It has an excellent tolerance and safety profile that makes it appropriate for repeated follow-up examinations.

EUS-guided-liver biopsy (EUS-LB) may be safer than its percutaneous counterpart for performing hepatic tissue sampling in patients with coagulation disorders, such as those with liver cirrhosis [13, 14]. The 19-gauge biopsy needle, which is smaller than the 16-gauge needles traditionally used in transcutaneous LB, can be oriented under direct vision into the liver for sampling avoiding puncturing larger vessels [15]. Abdominal skin surgical scars, ascites or dense abdominal wall thickness are also not limitations. Few studies compared the yield of percutaneous versus EUS-guided liver sampling, concluding that specimen adequacy and diagnostic yield are at least comparable between both techniques, ranging from 90% to 100% [16]. Recently, a comparison between “blind” liver biopsies using different commercially available 19-gauge needles (Cook Echotip Procore, Olympus EZ Shot 2, Boston Scientific Expect Slimline, Covidien SharkCore) was performed and the Covidien Sharkcore needle produced statistically superior histological specimens by capturing more complete portal tracts, possible due to its design [17].

Focal liver lesions

EUS is a useful adjuvant to CT and MRI in diagnosing and characterizing focal liver lesions (FLL) [18, 19]. Several studies [4, 20–22] have showed superiority of EUS over CT in detecting FLL, especially when they are small (<1 cm) or located in the left lobe or hilum. Awad et al. showed that EUS could diagnose additional hepatic lesions in 28% of patients with a history of known liver mass that were detected initially by CT [20].

Aside from detection, EUS may differentiate the etiology of these lesions using several tools.

First, a validated EUS scoring system has been developed, with a positive predictive value of 88% [23]. With this system, the presence or absence of certain criteria increases the accuracy to differentiate between malignant, benign or indeterminate FLL. Benign solid FLL are distinct hyperenhanced and/or have a distinct geographic shape, while malignant lesions must have at least three of the following characteristics: two components (with isoechoic/slightly hyperechoic center or without isoechoic/slightly hyperechoic center), post-acoustic enhancement, adjacent structure distortion, hypoechoigenicity (slightly or distinctly) and/or at least 10 mm.

Second, EUS-elastography has been described in two studies [24, 25] as a valuable tool in detecting, characterizing and differentiating between benign and malignant FLL with sensitivity, specificity and diagnostic accuracy of 92.5%, 88.8% and 88.6%, respectively. More high-quality data are needed to confirm the potential of EUS-elastography in this field.

Third, differentiation between different types of FLL can also be studied through vascular enhancement patterns with CE-EUS, as is also done with CE-US [26]. Typical enhancement patterns are arterial hyperenhancement with subsequent slow washout in late-phase contrast in hepatocellular carcinoma (HCC), arterial hyperenhancement with rim-like enhancement and subsequent rapid washout in metastatic liver cancer [27].

Peripheral nodular hyperenhancement, with centripetal progressive fill-in in hemangioma, and arterial hyperenhancement with progressive, centrifugal complete, early, spoke-wheel arteries, unenhanced central scar in focal nodular hyperplasia [28].

Moreover, CE-US recently has been considered a useful tool for evaluating the effects of treatment of HCC. It can dynamically observe tumor vessel perfusion with superior diagnostic performance for residual tumors after transarterial chemoem-
bolization (TACE) compared to CE-CT (sensitivity and accuracy of detecting residual tumor with CE-US 95.6% and 96.2% versus CE-CT 76.2% and 77.7%, respectively) [29]. For this particular indication, CE-EUS could be of value, with the advantage of better examining the deeper liver lesions not visualized with CE-US [30]. However, this needs further confirmation.

In addition to the tools described above, EUS-guided tissue sampling can confirm a HCC diagnosis and avoid unnecessary surgery [22, 31–48] (▶ Fig. 5).

Currently, EUS-guided sampling is indicated “if the pathological result is likely to affect patient management and the lesion is poorly accessible/not detected at percutaneous imaging or a sample obtained via the percutaneous route repeatedly yielded an inconclusive result” [15]. If cytohistopathological results are inconclusive, KRAS mutation can be analyzed as it provides high diagnostic yield in EUS-guided histopathological evaluation [49]. To reduce the number of needle passes and potential adverse events (AEs), novel ancillary techniques are being developed. A recent study [50] conducted in animal models demonstrated technical feasibility of in vivo cytological observation using a high-resolution microendoscopy (HRME) system under EUS guidance. The authors concluded that HRME could obtain clear images representing cytology-level morphology of liver and would therefore improve diagnostic accuracy of EUS-FNA for liver lesions. EUS-FNA may also play a significant role in staging HCC in patients with cirrhosis with PV thrombus by differentiating a tumor thrombus from a clot, as its etiology is difficult to assess in the absence of characteristic hallmarks [51–55]. This is of paramount importance in HCC management, as patients with tumor invasion into the PV are deemed to have unresectable disease and to be ineligible for transplant [56]. EUS-FNA of splenic vein thrombus has also been performed to clarify its etiology (benign versus malignant) [57]. A systematic review concerning complications related to EUS-guided sampling showed a 2.33% rate of morbidity (bleeding, infection, pain, fever) and 0.29% rate of mortality (due to uncontrollable cholangitis) after 344 EUS-FNA of hepatic lesions [58]. Due to the long path required to reach the liver capsule and the fact that HCC is more vascular in comparison with other cancers (for example, pancreatic), one could presume a higher risk of tumor spillage into the peritoneal cavity along the needle track. Nonetheless, no such cases have been reported so far.

Lastly, convex EUS-Doppler can provide staging information regarding vascular invasion at the hepatic hilum, an important parameter to evaluate in, for example, peri-hilar cholangiocarcinomas [59].

Liver cirrhosis

Detection of liver fibrosis has important management and prognostic implications. Traditionally, liver biopsy is considered the “gold standard” diagnostic method for identifying liver cirrhosis, but has drawbacks regarding sampling errors, interobserver variability and complications [60]. Noninvasive fibrosis markers, such as liver stiffness measurements (transient elastography – Fibroscan – and real-time elastography), have been developed to overcome these problems. Nonetheless, applicability of these measurements with a transabdominal approach is lower in cases of obesity or ascites and in discriminating between intermediate stages of fibrosis [60]. In addition, real-time elastography, used in EUS, can be advantageous over transabdominal Fibroscan, as it can estimate liver stiffness in all patients (either obese or not) and has the potential to differentiate between fibrosis and steatosis, as liver steatosis has a distinct appearance on real-time sono-elastography images, with low mean hue histogram values [61]. Further studies are needed, however, to confirm these hypotheses.
If histological confirmation is needed, EUS-guided LB is a safe technique with a diagnostic yield for liver parenchymal disorders such as liver cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis and NAFLD between 91% and 100% [62–73], which is at least comparable to percutaneous or transjugular routes [16, 74, 75]. Few complications have been reported with this technique. Four self-limited pericapsular hematomas [72–74], two cases of duodenal perforations [23], one self-limited bleeding [62] and a case of a near-fatal hemorrhagic shock after EUS-LB [76] have been reported so far. Data on patient preference regarding being submitted to a percutaneous versus EUS liver biopsy are missing.

Portal hypertension

Detecting vascular changes within and outside of the upper digestive wall

EUS-Doppler has a higher sensitivity for detecting esophageal and gastric varices compared to upper endoscopy [5, 77–85] (Fig. 6).

It is also a useful modality for evaluating ectopic duodenal varices [86–90]. The higher the grade of esophageal varices, the higher the EUS sensitivity [82]. Success in visualizing small esophageal varices by EUS can be improved by using small water-filled balloons [77], small 20-Hz ultrasound transducers [91, 92], videotaped high-resolution endoluminal sonography [81] or high-frequency ultrasound miniature probes [93].

EUS-doppler can diagnose collateral veins, which are found adjacent to or outside the esophageal wall in patients with esophageal varices [5–9]. There is a correlation between grade of esophageal varices and development and diameter of para-ECV [5] and between diameter of the splenic vein and diameter of these collaterals [94].

EUS-Doppler can also substantiate diagnosis of portal gastropathy, showing diffuse thickening of the gastric wall with dilated paragastric veins [6, 95], thereby distinguishing it from watermelon stomach, which is characterized by focal swelling and spongy appearance in mucosa and submucosa [96, 97]. It is also valuable in differential diagnosis of giant gastric folds [98, 99], distinguishing benign causes, such as gastric varices, from malignant causes.

Dynamic assessment of hemodynamic changes

The hepatic venous portal pressure gradient or portal pressure gradient (PPG) reflects the degree of PHT and is the single best prognostic indicator in liver disease. Currently, PPG measurement via right jugular vein access is considered the gold standard. Nonetheless, this is an indirect invasive measurement because it relies on a wedge pressure to assess portal vein pressure, and may not always accurately reproduce true PV pressures. EUS-guided PV catheterization was developed to overcome drawbacks of the transjugular approach. It was first performed in porcine models [100–105], appearing feasible and safe for portal pressure measurements as well as for portal angiography and pressure measurements. The first human clinical report was made by Fuji-Lau et al. [106]. Later, a human study [106, 107] involving 28 patients demonstrated a 100% technical success and no AEs in measuring the PPG with a linear echoendoscope, a 25G FNA-needle and a compact manometer. An excellent correlation was found between PPG measurement, clinical evidence of PHT, and clinical suspicion of liver cirrhosis. Larger clinical trials and comparative studies between both approaches are needed to confirm and establish the role of this technique.

Prediction of variceal bleeding and rebleeding

Elevated intravariceal pressure is associated with risk of variceal bleeding. In 1999, Jackson et al. developed a technique for directly measuring esophageal variceal wall tension using an ultrasonographic transducer and needle puncture of the varix [108]. Later, to avoid risk of variceal bleeding from needle puncture, Miller et al. [109, 110] developed a noninvasive EUS-based device by which they successfully measured intravariceal pressure in a varix model by placing a 20-MHz ultrasound transducer in a latex balloon catheter sheath and attaching the catheter to a pressure transducer. Another indirect measurement of intravariceal pressure has been developed using EUS-Doppler-guided manometry of esophageal varices, using a linear EUS.
probe with power Doppler to assess flow in the varices and a manometry balloon attached to the tip of the probe [111]. Nonetheless, despite being promising, none of these methods are in widespread use today.

Other EUS predictors have also been found in relation to risk of variceal bleeding. Hematocystic spots on the surface of esophageal varices, identified in EUS as saccular aneurysms, are closely associated with high risk of variceal rupture [81, 112]. By summing the cross-sectional surface area of all esophageal varices in the distal esophagus with digitized image, EUS can predict the risk of variceal bleeding: for each 1 cm² increase in variceal cross-sectional surface area (CSA) the risk of variceal bleeding increases 76-fold per year [113]. Using a cutoff value for the CSA of 0.45 cm², sensitivity and specificity for future variceal bleeding above and below this point are 83% and 75%, respectively [113]. Furthermore, high blood flow variceal velocities and thin gastric variceal wall (mean thickness of the gastric wall of 1.2 ± 0.2 mm) correlate with greater bleeding risk [114]. Number and size of para and peri-ECV [115, 116] and perforating veins [117, 118] are also associated with risk of variceal bleeding.

EUS has a predictive value identifying rebleeding risk from esophageal varices by evaluating the type and grade of esophageal collaterals and cardiovascular structures [80, 119, 120]. Collateral vessels in the vicinity of gastric cardia improve after endoscopic variceal ligation (EVL), indicating that esophageal varices can be treated by EVL even though they connect with cardia varices. Their disappearance is associated with longer periods free from recurrence of esophageal varices [121]. Patients with peri-ECV and perforator veins [77, 115, 122–124] and/or with large para-ECV [83, 116, 125–128] are more likely to experience variceal recurrence and rebleeding. EUS can clearly predict recurrence of esophageal varices following EVL with a sensitivity and specificity of 89.2% and 90.5%, respectively [124].

Paraesophageal diameter after EVL is a better recurrence predictor, because it has a lower cut-off parameter, higher sensitivity, and higher area under a ROC Curve (AUROC) (4 mm, 70.6% sensitivity, 84.6% specificity, 0.801 AUROC) [127]. A study using balloon-occluded retrograde transvenous obliteration for management of gastric varices concluded that presence of esophageal varices and high gastric variceal resistance index assessed by EUS (≥0.24) before the procedure were significant risk factors for worsening of esophageal varices after obliteration [129]. Velocity of hepatofugal blood flow in the left gastric vein trunk can be determined, and also the branching pattern, both of which are associated with variceal recurrence after endoscopic treatments (anterior branch dominance and flow velocity of 12 c/s or more are associated with higher variceal recurrence) [118, 124, 130, 131].

Assessment of pharmacological effects

Variceal rupture results from increased variceal wall tension, which according to Laplace’s law, is determined by transmural pressure difference, size and wall variceal thickness. Based on this formula, few studies have shown that EUS morphological assessment of varices (column radius and volume) combined with simultaneous pressure measurement are objective and useful tools for risk stratification [132, 133]. The effects of somatostatin, octreotide, and terlipressin on azygos blood flow in patients with portal hypertension have also been well evaluated by EUS. EUS is capable of documenting a marked decrease of the azygos blood flow after injection of vasoactive agents, showing a potential role for monitoring pharmacological effects on the superior porto-systemic collateral circulation and portal venous flow in patients with portal hypertension [134–136].

In sum, there are several potential clinical applications of EUS in portal hypertension, namely in the evaluation of vascular changes of the digestive wall (through evaluation of esophageal and gastric varices, collateral veins and portal gastropathy), dynamic assessment of hemodynamic changes (through EUS-guided PV catheterization), prediction of variceal bleeding and rebleeding (through intravariceal pressure measurements, evaluation of hematocystic spots, summing the cross-sectional surface area of EV, calculation of type and grade of collateral veins) and assessment of pharmacological effects. Nonetheless, despite the multiplicity of possible uses, EUS currently does not have an established role in clinical practice to explore portal hypertension. More efficacy and safety data are needed.

Therapeutic role of EUS

EUS-guided liver tumor ablation/injection

Several EUS-guided liver tumor ablation/injection techniques have been described in the literature.

Radiofrequency ablation (RFA) is an alternative low-risk minimally invasive therapy for HCC and liver metastases when resection cannot be performed or, in case of HCC, when transplantation cannot be executed [137]. EUS-guided RFA with a prototype retractable umbrella-shaped electrode array has been created for effective coagulation necrosis of large areas, minimizing the risk of gastric mucosa damage [138]. More recently, a monopolar RFA under EUS guidance using a 1-Fr wire electrode (Habib) was introduced and tested in pig models [139, 140]. Its flexible and thinner electrode could facilitate tissue access. Although one study did not show definite coagulative necrosis in the liver [139], another study did show positive results [140]. Further studies are needed to fully examine the response of tumor tissues to EUS-RFA.

Cryothermy (Cool-Tipped RFA) is a new flexible ablation device with a hybrid cryotherm probe that combines bipolar RFA with cryotechnology allowing for more efficient tissue ablation in the setting of lower temperatures provided by the cooling cryogenic gas [141]. In a single study, EUS-guided transgastric cryotherapy ablation in porcine liver resulted in well-defined ablation areas without any complications [142].

Neodymium:yttrium-aluminum-garnet (Nd-YAG) laser ablation is a minimally invasive method for solid tumor destruction by directing low-power laser light energy into tissue. Its advantages are use of thinner needles, shorter application time and the ability to reuse and re-sharpen the needle, which can be used at different angles. Di Matteo et al. [143] reported the first human case of EUS-guided Nd:YAG laser ablation for treat-
ment of HCC located in the caudate lobe, with favorable prog-
nosis. More recently, a prospective study including 10 patients 
with HCC or liver metastasis from colorectal carcinoma conclud-
ded that EUS-guided laser ablation might be technically feasi-
ble in selected tumors of the caudate lobe and left liver [144]. 
Nonetheless, the safety of this modality must be further con-
firmed in future studies.

High-intensity focused ultrasound (HIFU) was first devel-
oped as a thermal ablation method to ablate prostatic tissue 
and later to ablate liver metastases surgically or via a transcuta-
neous approach. Recently, a EUS-HIFU device has been created 
with the aim of treating tumors localized near the gastric lumen 
without the difficulties of gas interposition. Two reports, per-
formed in living pig models, achieved complete necrosis of the 
lesions and had no immediate AEs [145, 146].

EUS-guided fine-needle ethanol injection was developed to 
deliver therapeutic agents to a target site more precisely and 
minimize damage to non-tumor tissue compared to the percu-
taneous approach. The efficacy and safety seen in the case re-
ports and case series of EUS-guided ethanol injection in HCC 
[147–150] and hepatic metastasis [151, 152] suggest a pro-
mising role for EUS in managing lesions that are difficult to ac-
cess with conventional methods. After EUS-guided ethanol liver 
tumor injection, a self-limited subcapsular hematoma [152] 
was reported.

EUS-guided iodine-125 brachytherapy is another palliative 
treatment. Although usually performed percutaneously, EUS-
guided iodine-125 brachytherapy can be a safe and effective al-
ternative for left-sided liver tumors refractory to transabdominal 
interventions [150].

EUS-guided portal injection chemotherapy (EPIC) using iri-
notecan-loaded microbeads in liver metastases can increase in-
trahepatic irinotecan concentrations while decreasing systemic 
exposure [153].

**EUS-guided fiducial placement for stereotactic body radi-
tation therapy**

Use of EUS-guided fiducial placement for stereotactic body ra-
diation therapy (SBRT) is becoming more widespread. Using 
multiple photon beams that intersect at a stereotactically de-
termined target, it delivers higher doses of radiation into the 
tumor while sparing surrounding normal tissue. As the liver is 
very radiosensitive, accurate targeting of the tumor while sal-
vaging normal hepatic parenchyma is crucial to prevent radia-
tion-induced liver injury. SBRT requires implantation of fiducial 
markers in the lesion for adequate detection. EUS-guided fidu-
cial placement seems to be a safe and technically feasible tech-
nique for preparing patients with deeper liver malignancies for 
SBRT that are not feasible for percutaneous approaches [154, 155].

**EUS-guided selective portal vein embolization**

Preoperative embolization of PV branches causing atrophy of 
the hepatic segments to be removed and subsequent compensa-
tory hypertrophy of the remaining segments has proven to be 
safe and effective in patients undergoing extensive hepatecto-
ymy [156, 157]. Matthes et al. [158] reported the first success-
ful EUS-guided selective PV embolization with Enteryx (ethyl-
ene-vinyl alcohol copolymer) in a single swine model.

**EUS-guided cyst ablation**

Most simple liver cysts require no treatment. However, when 
they become symptomatic, treatment is indicated. Surgery is 
the classical approach, but as it leads to considerable morbidity 
rates, other less-invasive modalities were developed. Percuta-
neous aspiration (US or CT-guided) with lavage therapy with a 
sclerosing agent has demonstrated encouraging results with 
minimal AEs. More recently, EUS-guided aspiration and lavage 
therapy with alcohol has been postulated as having the advan-
tage of not requiring insertion of a percutaneous drainage 
catheter, thus enabling alcohol lavage to be done with a one-
step approach and has been considered a preferred approach 
to left lobe cysts [159]. There is a newer sclerosing agent used 
in EUS-FNA (1 % lauromacrogol) that seems to have fewer side 
effects than traditional ethanol and can thus be used as a replac-
ement [160].

**EUS-guided liver abscess drainage**

Percutaneous drainage (PCD) is a first-line method for liver ab-
scess drainage because of its minimal invasiveness and high 
technical success rate [161, 162]. However, it has several disad-
antages, such as external-drainage and self-tube removal that 
may lead to patient discomfort. Recently, EUS-guided liver ab-
scess drainage (EUS-AD) has been developed with the advanta-
ges of doing one-step internal drainage (which has an obvious 
cosmetic benefit and avoids risk of self-tube removal and peri-
tonitis). Nonetheless, only a few cases have been reported 
[163–173]. Even fewer reports can be found on EUS-AD using 
fully-covered self-expandable metallic stents (fcSEMS) [168– 
172, 174]. SEMS are expandable and have a larger diameter 
compared to plastic stents, resulting in impaction between the 
stent and the surrounding drainage area or abscess wall, and 
thus potentially less leakage into the abdominal cavity. In addi-
tion, the larger diameter allows for a better drainage effect, ob-
viating the need for multiple sessions to clean the abscess and a 
lesser procedure time. If, however, a direct endoscopic necro-
sectomy is indicated, it can be easily performed through the 
large-bore stent. Finally, SEMS can also be helpful in hemostasis 
when unexpected bleeding from the tract occurs during the 
procedure. Ogura et al. [172] concluded that EUS-AD with 
fcsEMS is a potential first-line treatment for liver abscesses, 
particularly in the left liver lobe, as it is associated with shorter 
hospital stay, higher clinical success and lower AE rates compar-
ed to PCD. So far, only one case report has described a successful 
EUS-AD of the right hepatic lobe with SEMS [175].

Infected hepatic cysts are much rarer and only a single case 
has reported an effective EUS-guided drainage [176]. Rare in-
fected intracystic papillary hepatic adenocarcinomas have also 
been successfully approached by EUS [177].

**EUS-guided therapy for portal hypertension**

Apart from improving the diagnosis, EUS can also assist in the 
management of PHT.
Nagamine et al. [178] conducted a successful pilot study of a "modified" esophageal variceal ligation (EVL) technique using an EUS-color Doppler with the aim of decreasing variceal recurrence rate associated with traditional EVL. As it has been shown that persistence of patent varices, perforating veins or peri-ECV are associated with variceal recurrence, EVL performed with EUS can be advantageous compared to upper endoscopy as it can better identify these zones and assist in completing variceal eradication.

Esophageal varices can also be eradicated using EUS-guided sclerotherapy, as concluded in a randomized controlled study by Paulo et al. [179]. This procedure seems to reduce recurrence of esophageal varices after endoscopic therapy [180] and the azygus vein diameter [181]. Minor complications in EUS-sclerotherapy (as thoracic pain and self-limited bleeding) have been reported and do not seem to differ from the endoscopically induced complications [179].

For eradication of gastric varices, EUS-guided cyanoacrylate injection with/without coiling with precise injection in the collateral veins can be valuable, both for obtaining hemostasis during active bleeding and in primary and secondary bleeding prophylaxis [182–191] (▶Fig. 7).

EUS-guided cyanoacrylate injection with/without coiling has been also used for duodenal varices [86, 87, 192]. EUS can further be useful for evaluating adequacy of tissue adhesive in variceal obliteration [193]. EUS-guided cyanoacrylate injection has been associated with fever, chest pain, post-injection ulcers, and asymptomatic pulmonary glue embolisms [182]. These AEs, however, seem to be fewer than with endoscopy-guided injection [186].

EUS-guided coiling is another option for embolization of gastric varices [194]. It requires fewer procedures and has fewer AEs than EUS-guided cyanoacrylate injection although larger comparative studies are needed [182]. One coil migration into the liver was described, but passed spontaneously retrograde into the portal vein and assumed a final position in the subcapsular liver without clinical sequelae [195] and few cases of self-limited bleeding have occurred at the puncture site during the procedure [196]. AEs associated with EUS-guided coil application tend to be fewer than with EUS-guided cyanoacrylate injection [182]. Combining cyanoacrylate injection and coil embolization showed favorable results in large studies [183, 197]. Combining both carries a 7% AE rate (self-limited abdominal pain, pulmonary embolization, and bleeding) [187]. Good short-term outcomes after microcoil injection in anastomotic varices after total pancreatectomy have also been reported [196].

A case report of small bowel variceal bleeding demonstrated successful management using an EUS-assisted human thrombin injection [198].

▶Fig. 7 EUS-guided cyanoacrylate in varices. a EUS-doppler evaluation of varices. b EUS-puncture of the varix. c EUS-guided cyanoacrylate. d Varix total obliteration with the cyanoacrylate.
Finally, traditional transjugular intrahepatic portosystemic shunt (TIPSS), an effective treatment for PHT complications, can be technically challenging when performed in the setting of IVC and HV obstruction. In addition, catheter manipulation through the right atrium and intrathoracic IVC may be dangerous in patients with severe cardiopulmonary disease. EUS-guided IPSS creation [103, 199–201] was thus introduced as a potentially advantageous alternative as it does not require entrance into the heart or the IVC and decreases radiation exposure to both patient and physician during stent deployment. Also, it could become a valid therapeutic option in patients with active variceal bleeding that does not respond to endoscopic hemostasis and who are not stable enough to sustain transport to a radiology suite or when there is an anticipated delay before conventional TIPSS placement.

Limitations of EUS

The potential drawback of EUS when used for diagnostic purposes might be that it is invasive and expensive to perform. In addition, as already described, diagnostic accuracy is limited for lesions located in the right liver lobe or under the dome of the diaphragm. Presence of fatty infiltration, calcifications, pneumobilia, and extensive fibrosis may also interfere with ultrasound images. Altered anatomy (for example, presence of a pharyngeal diverticulum or a tight stricture), as is an upper gastrointestinal endoscopy, may also restrict EUS performance. Some of the EUS tools discussed here may also be unavailable. The endosonographer’s experience and diligence by which the liver is scrutinized are of critical diagnostic and therapeutic importance.

Patients included in the studies either had no cirrhosis or a compensated cirrhosis. To fully evaluate use of EUS interventions, it would be very interesting to incorporate patients with decompensated cirrhosis in the study population, as they are susceptible to higher rates of complications such as bleeding/infection.

A clear limitation of the current literature of EUS related to liver diseases is that the majority of the studies have been small, single-center, often retrospective and non-randomized. Experience with EUS interventional procedures in the liver remains limited mainly to animal feasibility studies and small human case series.

Therefore, although promising, much work needs to be done to firmly and scientifically establish the indication of diagnostic and therapeutic EUS in liver disease, including resolving issues pertaining its cost-effectiveness.

Conclusion

EUS has potentially significant clinical applications in diagnosis and treatment of liver disorders. It provides excellent, unobstructed, real-time imaging of the liver at high resolution. Adjunct tools such as Doppler, elastography, and contrast can be used to improve its diagnostic yield. EUS-guided interventional procedures to measure portal hepatic pressure, ablate hepatic tumors and cysts, and drain liver abscesses have great potential to be patient friendly, cost-effective treatment alternatives with limited risk of complications. It should also be recognized that EUS is limited in regard to right lobe access. All this potential calls for adequately designed, preferably randomized controlled studies to substantiate the promise of the technology and firmly establish the role of EUS in diagnostic and therapeutic algorithms for liver disorders.

Competing interests

None

References


[16] Pineda JJ, Diehl DL, Miao CL et al. EUS-guided liver biopsy provides diagnostic samples comparable with those via the percutaneous or transjugular route. Gastrointest Endosc 2016; 83: 360 – 365


[38] Reyes MCD, Huang X, Bain A et al. Primary pancreatic leiomyosarcoma with metastasis to the liver diagnosed by endoscopic ultrasound-guided fine needle aspiration and fine needle biopsy: A case report and review of literature. Diagn Cytopathol 2016; 44: 1070–1073


[74] Nieto J, Khaleel H, Challita Y et al. EUS-guided fine-needle core liver biopsy sampling using a novel 19-gauge needle with modified 1-pass, 1 actuation wet suction technique. Gastrointest Endosc 2018; 87: 469 – 475
[86] Curcio G. Case of obscure-overt gastrointestinal bleeding after pediatric liver transplantation explained by endoscopic ultrasound. Endoscopy International Open 2019; 07: E1272


Suzuki T, Matsutani S, Umebara K et al. EUS changes predictive for recurrence of esophageal varices in patients treated by combined endoscopic ligation and sclerotherapy. Gastrointest Endosc 2000; 52: 611 – 617


Schulman AR, Thompson CC, Ryoo M. EUS-guided portal pressure measurement using a digital pressure wire with real-time remote display: a novel, minimally invasive technique for direct measurement in an animal model. Gastrointest Endosc 2016; 83: 817 – 820


Miller L, Banson FL, Bazir K et al. Risk of esophageal variceal bleeding based on endoscopic ultrasound evaluation of the sum of esophageal variceal cross-sectional surface area. Am J Gastroenterol 2003; 98: 454 – 459

Sato T, Yamazaki K, Toyoda T et al. Observation of Gastric Variceal Flow characteristics by endoscopic ultrasonography using color Doppler. Am J Gastroenterol 2008; 103: 575 – 580

Irisawa A, Saito A, Obara K et al. Endoscopic recurrence of esophageal varices is associated with the specific EUS abnormalities: Severe periportal collateral veins and large perforating veins. Gastrointest Endosc 2001; 53: 77 – 84

Faigel DO, Rosen HR, Sasaki A et al. EUS in cirrhotic patients with and without prior variceal hemorrhage in comparison with noncirrhotic control subjects. Gastrointest Endosc 2000; 52: 455 – 462


Kume K, Yasamaki M, Watanabe T et al. Mild collateral varices and a fundic plexus without perforating veins on EUS predict endoscopic non-recurrence of esophageal varices after EVL. Hepatogastroenterology 2011; 58: 798 – 801


Leung VK, Sung JJ, Ahuja AT et al. Large paraesophageal varices on endosonography predict recurrence of esophageal varices and re-bleeding. Gastroenterology 1997; 112: 1811 – 1816

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\text{[138] Varadarajulu S, Jhala NC, Drelichman ER. EUS-guided radiofrequency ablation with a prototype electrode array system in an animal model (with video). Gastrointest Endosc 2009; 70: 372–376}
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\text{[148] DiMaio CJ. Sp616 EUS-guided ethanol ablation for management of metastatic hepatocellular carcinoma. Gastrointest Endosc 2013; 77: AB115}
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\]

\[
\text{[164] Ang T, Seewald S, Teo E et al. EUS-guided drainage of ruptured liver abscess. Endoscopy 2009; 41: E21–E22}
\]


[185] Iwase H, Suga S, Morise K et al. Color Doppler endoscopic ultrasonography for the evaluation of gastric varices and endoscopic obliteration with cyanoacrylate glue. Gastrointest Endosc 1995; 41: 150–154


